Table 1:
Patient and CAR T-cell Treatment Characteristics
| Patient ID | Age at CAR T-cell Therapy, Sex | MCL Histology & Ki67 (%) at Diagnosis | TP53 Status at Diagnosis | Prior Lines of Therapy: Total (CNS-directed) | Previous HCT | POD24 | CNS Disease Location & Symptoms | Disease Presence at Time of CAR T-cell Therapy | CAR T-cell Product | CRS: Max Grade, Duration (days); Treatment | ICANs: Max Grade, Duration (days); Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| A | 48, F | Blastoid; 95% | IHC: NA FISH: NA NGS: NA | 6 (3) | Yes, auto | Yes | LMD & Parenchyma; lower extremity weakness | Systemic: No CNS: Yes | Brexu-cel | - | - |
| B | 57, F | Blastoid; 50% | IHC: NA FISH: NA NGS: mutation absent | 3* (0) | Yes, allo | Yes | LMD; none | Systemic: Yes CNS: No | Brexu-cel | Grade 2, 5d; steroids, toci., anakinra | Grade 3, 16d; steroids, toci., anakinra |
| C | 51, F | NA 26% | IHC: NA FISH: NA NGS: mutation present | 4 (2) | No | Yes | Parenchyma; pan-hypopituitarism | Systemic: No CNS: Yes | Brexu-cel | Grade 1, 1d; no treatment | Grade 1, 8d; no treatment |
| D | 57, M | NA | IHC: NA FISH: del(17p) present NGS: NA | 4* (1) | Yes, auto | Yes | LMD; seizures | Systemic: No CNS: Yes | Brexu-cel | Grade 1, 8d; toci. | Grade 3, 3d; dex., anakinra |
| E | 79, M | Blastoid; 90% | IHC: NA FISH: no del(17p) NGS: mutation absent | 4* (0) | No | Yes | LMD & parenchyma; AMS | Systemic: Yes CNS: Yes | Brexu-cel | Grade 3, 8d; steroids, toci. | Grade 3, 23d; steroids, toci., IVIG |
| F | 64, M | NA | IHC: NA FISH: no del(17p) NGS: mutation absent | 2* (1) | No | No | Parenchyma; headache, CN palsy | Systemic: No CNS: No | Brexu-cel | Grade 2, 7d; steroids, toci., anakinra | - |
| G | 78, M | Classic; 10–20% | IHC: Positive (80%) FISH: NA NGS: NA | 7* (2) | No | Yes | LMD; vision loss | Systemic: No CNS: Yes | Brexu-cel | Grade 2, 6d; dex., toci. | Grade 3, 13d; dex., toci., anakinra |
| H | 64, M | Pleomorphic; 20% | IHC: NA FISH: NA NGS: mutation absent | 4* (1) | No | Yes | LMD; headache | Systemic: Yes CNS: Yes | Brexu-cel | Grade 1, 3d; toci. | - |
| I | 75, F | Pleomorphic; >95% | IHC: Positive (>95%) FISH: NA NGS: NA | 4* (1) | No | Yes | LMD; double vision (CN III palsy) | Systemic: Yes CNS: No | Brexu-cel | Grade 1, 4d; dex., toci. | Grade 3, 10d; dex., toci. |
| J | 44, F | Blastoid; 50% | IHC: NA FISH: NA NGS: NA | 4* (1) | No | Yes | LMD; bilateral CN VII palsies | Systemic: Yes CNS: Yes | Tisa-cel | Grade 1, 2d; dex. | Grade 1, 5d; dex. |
Indicates bridging therapy was received (defined as any therapy from time of apheresis to CAR T-cell infusion). allo, allogeneic; auto, autologous; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CNS, central nervous system; CRS, cytokine release syndrome; d, days; dex., dexamethasone; F, female; HCT, hematopoietic cell transplantation; ICANS, immune effector cell-associated neurotoxicity syndrome; IHC, immunohistochemistry; IVIG, intravenous immunoglobulin; LMD, leptomeningeal disease; M, male; MCL, mantle cell lymphoma; max, maximum; NA, not available; NGS; next-generation sequencing; POD24, progression of disease within 24 months of diagnosis; tisa-cel, tisagenlecleucel; toci., tocilizumab